About
Panaxia Pharmaceutical Industries specializes in the research, development, and manufacturing of medical cannabis. The company's goal is to align medical cannabis with formulation technologies and the highest available pharmaceutical standards. Panaxia currently manufactures a variety of standardized medical cannabis products including sublingual and oral tablets, metered-dose inhalers, creams, and suppositories. The company's products, manufacturing facility, and production processes are subject to stringent quality assurance procedures. Panaxia is part of the Panaxia Medical Devices and Pharmaceuticals Group. Panaxia's R&D center is located in Israel and is managed by senior scientists and graduates of the Weizmann Institute of Science. Panaxia offers more than 600 medical products in over 30 international markets to treat a wide range of symptoms and conditions.
Funding history · 3 rounds · $11.6M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What was Panaxia's status change in March 2024?
- In March 2024, Panaxia was acquired by Barak Investment House.
- What was the total amount Panaxia raised in funding?
- Panaxia raised a total of $11,598,700 in funding.
- When did Panaxia complete its reverse merger and on which exchange?
- Panaxia completed a reverse merger in September 2019 on the TASE.
- Which company did Panaxia partner with to enter new medical cannabis markets in Europe?
- In October 2022, Panaxia partnered with Neuraxpharm to enter new medical cannabis markets in Europe.
- When did Panaxia receive a production license for medical cannabis products in Malta?
- In May 2022, Panaxia announced it received a production license for medical cannabis products in Malta.
- What significant certification did Panaxia's facility in Malta receive in January 2022?
- In January 2022, Panaxia's facility in Malta was granted EU-GMP Standard certification.
- Which companies were the first to sell medical cannabis extracts for inhalation in Europe, according to a November 2021 report?
- In November 2021, Panaxia and Neuraxpharm were reported as the world's first companies to sell medical cannabis extracts for inhalation in Europe.
- What was Panaxia's strategic move regarding its Israeli retail operation in May 2021?
- In May 2021, Panaxia sold its Israeli cannabis pharmacy to focus on exports.
- Which country's government selected Panaxia to purchase premium medical cannabis oils in February 2021?
- In February 2021, the Government of Cyprus selected Panaxia to purchase its premium oils for the country's medical cannabis patients.
- When did Panaxia receive a marketing permit for medical cannabis products in Germany, making it the first Israeli company to do so?
- In November 2020, Panaxia became the first Israeli company to receive a marketing permit for medical cannabis products in Germany.